Trial
NCT04393038
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Abivax S.A.
Collaborators
—
Condition
COVID-19
Intervention
ABX464
Why stopped
Interim analysis concludes that the study is futile
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-26